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The human microbiota, which plays an important role in health and
disease, uses complex carbohydrates as a major source of nutrients.
Utilization hierarchy indicates that the host glycosaminoglycans
heparin (Hep) and heparan sulfate (HS) are high-priority carbohy-
drates for Bacteroides thetaiotaomicron, a prominent member of the
human microbiota. The sulfation patterns of these glycosaminogly-
cans are highly variable, which presents a significant enzymatic chal-
lenge to the polysaccharide lyases and sulfatases that mediate
degradation. It is possible that the bacterium recruits lyases with
highly plastic specificities and expresses a repertoire of enzymes that
target substructures of the glycosaminoglycans with variable sulfa-
tion or that the glycans are desulfated before cleavage by the lyases.
To distinguish between these mechanisms, the components of the
B. thetaiotaomicron Hep/HS degrading apparatus were analyzed.
The data showed that the bacterium expressed a single-surface
endo-acting lyase that cleaved HS, reflecting its higher molecular
weight compared with Hep. Both Hep and HS oligosaccharides
imported into the periplasm were degraded by a repertoire of lyases,
with each enzyme displaying specificity for substructures within these
glycosaminoglycans that display a different degree of sulfation. Fur-
thermore, the crystal structures of a key surface glycan binding protein,
which is able to bind both Hep and HS, and periplasmic sulfatases
reveal the major specificity determinants for these proteins. The locus
described here is highly conserved within the human gut Bacteroides,
indicating that the model developed is of generic relevance to this
important microbial community.
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The human colonic microbiota (CM) is crucial to health (1–3).The composition of the CM depends on its ability to access
nutrients, which are primarily dietary and host glycans. Dissecting
the mechanisms by which complex carbohydrates are used by the
CM is critical to understanding the drivers of the ecology of this
microbial community and how this process relates to human health.
The major glycan degraders in the CM are the Bacteroidetes (4–
6). These organisms access their target polysaccharides through
endo-acting enzymes on the bacterial surface followed by import of
the oligosaccharides generated, which are depolymerized in the
periplasm. The genes encoding these enzyme systems are physically
linked into loci termed polysaccharide utilization loci (PULs) (7). A
significant proportion of the complex carbohydrates available to the
CM is mammalian in origin (4). Despite this knowledge, our un-
derstanding of how the CM accesses host/mammalian glycans is
fragmentary. Models for the breakdown of high-mannose and
complex N-glycans by gut Bacteroides have been proposed (8), and
the ecological significance of removing terminal sialic acid from the
epithelial mucosa is established (9). There is, however, a paucity of
information on the mechanism by which glycosaminoglycans
(GAGs), such as heparin (Hep) and heparan sulfate (HS), are used
by the CM. HS is a major component of the extracellular matrix of
mammalian cells and therefore, likely to be available to the gut
microbiota via turnover of epithelial cells, whereas Hep is released
from mast cells at sites of injury and therefore, may not be as
prevalent as HS in the gut (10, 11).
Microbial utilization of Hep and HS poses significant biological
challenges. Both glycans differ significantly in their degree of po-
lymerization (DP), which suggests that degradation may occur in
different cellular locations, whereas sulfation patterns and the
uronic acid (UA) are also variable (Fig. 1) (10). This substantial
heterogeneity indicates that either a complex portfolio of enzymes
is required to deconstruct these acidic glycans or the enzymes that
mediate this process display significant substrate promiscuity. The
depolymerization of UA-containing glycans, such as Hep/HS, is
mediated by glycoside hydrolases (GHs) and/or polysaccharide ly-
ases (PLs) that are grouped into sequence-based families in the
CAZy database (12). Hep/HS are degraded by bacterial PLs be-
longing to families PL12, -13, and -21. Based on specificity, these
PLs can be further broadly grouped into three functional groups,
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Hep I–III. Hep I lyases require sulfation, Hep II PLs exhibit pro-
miscuity with respect to sulfation patterns, and Hep III enzymes
cleave low-sulfation regions of these GAGs (13, 14). The lyases
generate products capped by Δ4,5-unsaturated UA, which is re-
leased from the GAG by GHs from family GH88 (13). In addition,
some GAG-specific sulfatases have been characterized (15).
Although enzymes active against Hep and HS have been de-
scribed, how these PLs, GHs, and sulfatases are tailored to act in
unison to address the sulfation problem posed by these GAGs is
unclear. Several scenarios can be proposed, including desulfation
before backbone cleavage, the exploitation of broad specificity PLs
that can cleave Hep and HS independent of their sulfation, or the
recruitment of a consortium of lyases, with each enzyme targeting
specific substructures in these GAGs that differ in their sulfation
profiles. Similarly, the mechanisms by which the cell surface glycan
binding proteins (SGBPs), which contribute to the glycan degra-
dation machinery, target conserved features of these heteroge-
neous glycans are unknown.
Bacteroides thetaiotaomicron (Bt), a member of the CM, uses
Hep and HS as high-priority nutrient sources that activate a single
PUL (PULHep) (16). Here, we have dissected the mechanism by
which the enzymes and binding proteins encoded by this locus fully
deconstruct these highly variable GAGs and thus, solve the sul-
fation problem. Crystal structures of key proteins provide mecha-
nistic insight into substrate and ligand recognition. The data
revealed how the specificity of the apparatus is optimized to target
the repertoire of GAG structures presented to the bacterium at the
different stages of the degradative process.
Results
Structure of HS and Hep. Hep and HS are composed of a disac-
charide repeating unit comprising a UA, D-glucuronic (GlcA),
or L-iduronic acid (IdoA) alternating with D-glucosamine (GlcN).
GlcN is linked α1,4 to the UA, whereas IdoA and GlcA are linked
α1,4 and β1,4, respectively, to the amino sugar (10) (Fig. 1). GlcN
can be sulfated on O6 and sulfated or acetylated at N2 (GlcNAc),
whereas the UAs are often sulfated on O2. Hep contains signifi-
cantly more IdoA than HS and is almost completely sulfated,
whereas HS varies in its sulfation pattern, containing highly sul-
fated regions (Hep-like) and areas that contain little or no sulfation
(Fig. 1). The DP of Hep (∼40) is substantially less than that of
HS (∼80–200).
PULHep Structure. Bt grows on Hep, HS, and N-acetyl-de–O-sulfated
heparin (ΔSHep) (Fig. S1) (16, 17). Transcriptomics of Bt cultured
on Hep indicate that only PULHep, extending from bt4652 to
bt4675, was up-regulated in response to this GAG (16). The locus
encodes PLs, sulfatases, a GH88, and a member of the repressor,
ORF, kinase (ROK; Pfam PF00480) family (Fig. 1). In addition,
the sulfatase BT1596 is also up-regulated by Hep (15). PULHep
encodes a single SusC/SusD-like outer membrane glycan trans-
porter system and a potential SGBP (Fig. 1). In silico analysis of
the occurrence of PULHep suggests that it is widely distributed
within the Bacteroides and retains high sequence conservation and
synteny (Fig. S2).
SGBPs. The extracellular location of the putative SGBP, BT4661,
was revealed by immunofluorescence and proteinase K treatment
using antibodies against the protein (Fig. S3 A and B). Immuno-
precipitation of BT4661 fromHep-grown cells followed byWestern
blotting revealed the presence of BT4659SusD-like, indicating that
the two proteins physically associate (Fig. S3C). The interaction
between the PUL-encoded SGBP and SusD-like is consistent with
previous data from the starch utilization system of Bt (18). The
importance of BT4659SusD-like in Hep/HS utilization was high-
lighted by the severe lag (>20 h) displayed by Δbt4659SusD-like on
these GAGs (Fig. S1A). By contrast, Δbt4661SGBP had no growth
defect on HS or ΔSHep but had a noticeable phenotype when
grown on Hep-derived oligosaccharides (Fig. S1A, Inset). These
data suggest that the SGBP plays a role in oligosaccharide scav-
enging rather than polysaccharide acquisition, such as observed in
Bacteroides ovatus-mediated xyloglucan degradation (19).
Glycan specificity. Isothermal titration calorimetry (ITC) (Fig. 2A
and Table S1) revealed that BT4661SGBP bound tightly to both
Hep and HS (Kd ∼ 3 μM) but did not bind to other GAGs. No-
tably, coverage on both GAGs was similar, suggesting the protein
can tolerate both sulfated and unsulfated regions and could in-
teract or accommodate the different UAs and neutral sugars in
Hep and HS (Fig. 1). BT4661SGBP bound to oligosaccharides with
a DP ≥ 4, with affinity increasing up to DP = 6 to a level similar to
Hep. These data indicate that the BT4661SGBP binding site can
accommodate a hexasaccharide and supports the ability of the SGBP
to tolerate/recognize sulfation and IdoA at all subsites (Table S1).
These data show that BT4661SGBP is an SGBP of the Hep/HS
degrading apparatus and that the protein can accommodate a range
of Hep-based GAG structures.
BT4659SusD-like bound Hep, HS, and ΔSHep with similar affin-
ity, but the Kd was ∼20- to 30-fold lower than that for the
BT4661SGBP. Differences in affinity between the SusD-like and
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Fig. 1. Model for degradation of Hep and HS by Bt. (A) Schematic of the
PULHep locus in Bt. IM, inner membrane. (B) Schematic representation of the
cellular location, activity, and specificity of the PULHep-encoded enzymes and
glycan binding proteins. A typical HS structure is shown. The proteins for
which X-ray crystallographic structures were determined in this work are
represented by thumbnail images of the structure.
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cognate SGBP have been reported previously and may reflect
the proposed different roles that these proteins play in glycan
utilization (5, 19).
Structure of full-length BT4661SGBP. The crystal structure of
BT4661SGBP (Table S2) revealed six discrete domains that adopt an
Ig-like fold (Fig. 2B). This multi–Ig-like domain structure is com-
mon to the other three SGBPs, which have structures that are
known, although little or no sequence identity is evident between
these proteins (5, 19, 20). The domains, defined as D1 (N terminus)
to D6 (C terminus), are arranged in an extended, curved confor-
mation. Interdomain proline residues may limit the flexibility of the
SGBP (19). Small angle X-ray scattering (SAXS) on full-length
BT4661SGBP in the presence and absence of Hep gave the same
Rg and Dmax values for both conditions (Table S3), indicating that
no large conformational changes are imposed by the target GAG
(Fig. 2C, SI Results, and Fig. S3D).
Structure of truncated BT4661SGBP bound to oligosaccharide.Attempts to
obtain a ligand complex of full-length BT4661 were unsuccessful. A
truncated form of the protein comprising only D5 and D6 displayed
similar ligand binding to the WT SGBP. The crystal structure of
the D5/6 derivative (TrBT4661SGBP) was determined in complex
with a fully sulfated, Hep-derived unsaturated hexasaccharide
(Δ4,5UA2S-GlcNS6S-IdoA2S-GlcN6S-IdoA2S-GlcNS6S) (Fig. 2
D–F and Table S2). The binding site is formed across the D5
and D6 domains, with the reducing end of the hexasaccharide,
GlcNS6S, lying in D6 (subsite 1) and the nonreducing end ΔUA2S
located in D5 (subsite 6). D6 and D5 house sugars 1–4 and 5 and
6 of the hexasaccharide, respectively. The presence of the glycan
binding site on the C-terminal domain of an extended multidomain
SGBP has been observed previously and may be an adaptation to
enable ligand binding to occur at a distance from the cell surface
(19). Similar to other GAG binding proteins, interactions between
ligand and protein mainly involved basic amino acids rather than
aromatic residues, which is the characteristic signature of protein–
carbohydrate recognition of neutral glycans (10, 19–21). Alanine
scanning mutagenesis revealed that K505, R581, and R582 are the
key residues involved in ligand binding (Fig. S3E). R582 and
K505 interact with the carboxylates of the UA at subsites 2 and 6,
respectively, whereas R581 interacts with O3 of the reducing end
sugar. These interactions will be conserved in all Hep-based GAGs,
providing an explanation for the ability of BT4661 to recognize
both HS and Hep with similar affinity.
Enzymes Encoded by PULHep. The activity of the PLs sulfatases and
GH encoded by PULHep was determined against different sub-
strates, and the growth of mutant strains lacking active forms of
these enzymes on Hep, HS, and ΔSHep was assessed (Fig. S1 B–F).
Surface lyase BT4662PL12. The lipoprotein BT4662PL12 was shown to
be a surface enzyme (Fig. S3B) that was active on Hep,ΔSHep, and
HS, with a preference for the latter substrate (Fig. 3A and Table
S4). Aerobic whole-cell assays, which report only on the activity of
surface enzymes, showed that the pattern of reaction products
closely matches that of recombinant BT4662PL12 (Fig. S4A), con-
firming the cellular location of the PL. The range of oligosaccha-
rides generated during the early stages of GAG degradation points
to an endo-activity (Fig. 3A and Fig. S4E). In other characterized
PULs, a surface endo-acting glycanase plays a key role in poly-
saccharide utilization by generating oligosaccharides that are of an
appropriate size to be transported by the SusC/D-like apparatus (5).
However, the Δbt4662PL12 Bt mutant displayed only a partial
growth defect on HS (Fig. S1B), likely reflecting the heterogeneity
of the DP of the GAG; thus, the smaller forms of this glycan were
able to be transported into the periplasm of Bt without the need for
prior depolymerization. Growth on Hep and ΔSHep was not im-
paired in the Δbt4662PL12 mutant, reflecting their low DP, which
likely enables these molecules to be transported into the periplasm
without prior enzymatic processing.
End point assays revealed that Hep was almost completely in-
accessible to BT4662PL12 (only ∼5% degradation), whereas the
depolymerization values of HS and ΔSHep were ∼40 and ∼80%,
respectively (Table S5). Against HS, the limit products comprised
a wide range of products, whereas complete degradation of ΔSHep
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Fig. 2. Structural and biochemical characterization of the PULHep-encoded
SGBP BT4661. (A) ITC traces for (Upper) BT4661SGBP and (Lower) BT4659SusD-like
against HS and Hep. (B) Cartoon representation of BT4661SGBP colored from
blue to red from the N terminus to the C terminus. Each of six discrete domains
is labeled. Gray spheres show the positions of the interdomain prolines.
(C ) SAXS envelopes (gray mesh) for (Upper) apoBT4661SGBP and (Lower)
BT4661SGBP + Hep. The best fit of the crystal structure of BT4661SGBP (colored from
blue to red from the N terminus to the C terminus) is shown inside the SAXS
envelopes. (D) 2Fo-Fc map contoured at 1.0 sigma for fully sulfated Hep-derived
hexasaccharide in complex with BT4661SGBP. (E) Structure of D5 and D6 C-terminal
domains of BT4661SGBP bound to Hep hexasaccharide (carbons as yellow sticks).
(F) Ligand binding site of BT4661SGBP bound to fully sulfated Hep hexasaccharide.
Amino acid side chains are shown in green, the sugars are in yellow, and H bonds
between the ligand and protein are black dotted lines. The residues labeled in red
are critical for ligand recognition. The six sugar binding subsites are labeled one to
six from the reducing end of the oligosaccharide.
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generated oligosaccharides with a DP of 2–10 (Fig. 3A and
Fig. S4E). BT4662PL12 was only active against Hep oligosaccha-
rides with a DP ≥ 10 (Table S4). These data suggest BT4662PL12
has a large substrate binding cleft, in which sulfate groups can only
be accommodated at specific positions, and the enzyme displays an
endo mode of action, with limited processivity. These data are
consistent with a role for the enzyme in depolymerizing high mo-
lecular weight GAGs, such as HS, at the bacterial surface.
Periplasmic PLs. Based on proteinase K treatment and the product
profiles of whole-cell assays compared with those of the recombi-
nant enzymes, the majority of the polysaccharide-degrading en-
zymes encoded by PULHep are located in the periplasm (Figs. S3B
and S4A) and display no evidence for metal dependence. A unifying
feature of the three periplasmic PLs, BT4652PL15, BT4657PL12, and
BT4675PL13, is the appearance of limit disaccharide products during
the initial phase of degradation (Fig. 3 B–D). This activity is in-
dicative of a degree of processivity and likely results in rapid pro-
duction of the disaccharides that act as the signaling cue(s) required
to up-regulate PULhep (17). The three periplasmic lyases have
differing preferences for Hep, HS, and ΔSHep (described in detail
below), reflecting the ability of Bt to use these three substrates.
BT4657PL12 exhibited the greatest activity against HS and could
access ∼50% of the polymer; while against Hep, the lyase cleaved
27% of the glycosidic bonds (Tables S4 and S5). The enzyme
completely degraded ΔSHep to a single unsulfated disaccharide
species (Fig. 3B and Tables S4 and S5). During the initial degra-
dation of ΔSHep, BT4657PL12 generated a range of oligosaccha-
rides, with the disaccharide being the dominant product (Fig. 3B
and Fig. S4E). These data indicate that BT4657PL12 is primarily
endo-acting, with a degree of processivity. The products generated
from partially sulfated oligosaccharides showed that BT4657PL12 is
unable to accommodate 2-O sulfation of UA in its active site
(+1 subsite), explaining why the enzyme displayed limited activity
against Hep (SI Results).
In contrast, BT4675PL13 displayed highest activity against Hep
and was inactive against ΔSHep, consistent with a previous study
suggesting that sulfation was required for activity (Table S4) (22).
The requirement for sulfation was mirrored in the end point as-
says, which showed almost complete digestion of Hep but only
∼50% of HS (Table S5). The PL13 enzyme generated a range of
different size products indicative of an endo mode of action but
also displayed significant processivity, because UA2S-GlcNS6S
was the dominant product early in the reaction (Fig. 3C).
PL15 enzymes have previously only been shown to be alginate
lyases (23). BT4652PL15, however, was active on all three GAGs
tested. The enzyme was ∼800-fold more active against fully sulfated
Hep oligosaccharides compared with ΔSHep, indicating that sul-
fation was key for optimal activity (Table S4), consistent with the
production of UA2S-GlcNS6S, UA2S-GlcNS, and UA-GlcNS6S
from Hep; however, against HS, an additional disaccharide, UA-
GlcNAc6S, was generated, and the unsulfated disaccharide UA-
GlcNAc was produced only from ΔSHep (Fig. 3D). BT4652PL15
generated disaccharides against all substrates; no intermediate
products were observed during initial degradation (Fig. 3D and
Fig. S4D). These data indicate the enzyme is exclusively exo-
processive and can accommodate sulfates at all positions of the
substrate. Although sulfation is not essential, it is a specificity
determinant, and as such, BT4652PL15 displays more substrate
flexibility than BT4675PL13.
The data described above suggest that BT4652PL15 and BT4675PL13
can target similar heavily O-sulfated regions of Hep and HS, al-
though the PL15 enzyme can, in addition, cleave sparsely sulfated
regions of these GAGs. Consistent with this view is the observation
that mutant strains lacking BT4652PL15 or BT4675PL13 displayed
growth defects on Hep and to a lesser extent, HS but not ΔSHep
(Fig. S1 B–E). The growth properties of Δbt4657PL12 revealed
a significant role for BT4657PL12 in HS degradation. The
endo-acting lyase likely cleaves areas low in sulfation, creating
nonreducing ends that are targeted by BT4652PL15 and BT4675PL13.
Our data thus provide a biological context for the multiple lyases
expressed by Bt in response to Hep and HS (Discussion). The pri-
mary substrates for BT4675PL13 and BT4657PL12 are regions of
the GAGs that were highly and poorly sulfated, respectively. The
Δbt4652PL15 strain had the largest growth defect on Hep, whereas
Δbt4652PL15/Δbt4657PL12 displayed little growth on HS and a
marked increase in the lag phase when cultured on ΔSHep
(Fig. S1D). These growth profiles suggest that BT4657PL12 and
BT4675PL13 produce oligosaccharides that only BT4652PL15 can
degrade, and thus, the additional flexibility in recognition by the
PL15 bridges the two complementary activities of the PL12 and
PL13 enzymes (discussed in detail below).
GH88 enzyme. BT4658GH88 belongs to a family of enzymes that
cleave the glycosidic linkage between the Δ4,5-unsaturated UA
and GlcN/GlcNAc disaccharides that are produced by GAG lyases.
The enzyme was not active when O2 of the UA was sulfated but
could accommodate sulfation at N2 or O6 of the neutral sugar,
mirroring the binding specificity of the PULHep hybrid two-com-
ponent system (HTCS) BT4663 (Table S6) (17). The tuning of the
specificity of the GH88 enzyme with that of its cognate HTCS is
analogous to that observed in the Bt chondroitin sulfate PUL, in-
dicating a conserved role for these enzymes in controlling the rate
of signal degradation during growth on GAGs (24). Although
BT4658GH88 displayed similar catalytic efficiencies against
GlcNS and GlcNAc, the Km and kcat for the sulfated sugar were
lower, suggesting that the N-linked sulfate contributes to sub-
strate binding but restricts product departure, leading to a
reduced kcat.
O-sulfatases. A previous study showed that BT15962S-sulf and
BT46566S-sulf are exo-acting O-sulfatases; BT15962S-sulf targets the
O2 sulfation of unsaturated UA at the nonreducing end of di- and
oligosaccharides, whereas BT46566S-sulf cleaves the O6-sulfate of
the monosaccharide GlcNAc6S or GlcNS6S but is inactive against
GalNAc6S (Table S6) (15). To explore the mechanism of substrate
recognition, the crystal structures of inactive forms of the two
Bt O-sulfatases were determined in complex with their substrates.
BT15962S-sulf and BT46566S-sulf share a conserved α/β hydrolase
fold comprising a single domain (Fig. 4, Upper and Table S2). Both
enzymes have a pocket topology with metal binding sites located at
the base of the pocket. Calcium was modeled into the BT46566S-sulf
ligand-bound structure, whereas no metal was observed in
BT15962S-sulf (Fig. 4, Lower). Alanine substitution of the residues in
this pocket inactivated both enzymes, revealing the active site lo-
cation (SI Results and Table S6).
Inactive forms of BT15962S-sulf and BT46566S-sulf were cocrys-
tallized with ΔUA2S-GlcNS6S and GlcNS6S, respectively (Fig. 4).
BT15962S-sulf and BT46566S-sulf were inactive when expressed in
Escherichia coli, because the enteric bacterium cannot convert
S64 and S77, respectively, into formylglycine, which functions as
the catalytic nucleophile [to generate the formylglycine in E. coli,
the catalytic serine was mutated to cysteine because the bacterium
can convert cysteine to formylglycine (25)]. The essential histidines
H188 in BT15962S-sulf and H196 in BT46566S-sulf are in close
proximity to the scissile bond (Fig. 4, Lower and Table S6). Thus,
H188 and H196 are ideal candidates for the catalytic acid that is
required to protonate the O2/O6 of the departing sugar after nu-
cleophilic attack by the formylglycine and formation of a sulfate–
enzyme intermediate, which is then cleaved via a β-elimination to
complete the catalytic cycle.
In BT15962S-sulf, the carboxylate of ΔUA2S makes a bidentate
ionic interaction with R237, and loss of this interaction (R237A)
results in a 2,000-fold reduction in catalytic efficiency (Fig. 4A and
Table S6). This interaction is likely the major specificity de-
terminant used by the enzyme and explains why the sulfatase acts
on chondroitin disaccharides, which also possess O2-sulfated UA.
In BT46566S-sulf, R363 and D361 coordinate O4, and mutation of
R363 to Ala caused an ∼500-fold decrease in activity, whereas
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D361A was inactive (Table S6). These amino acids are likely
specificity determinants for gluco- over galacto-configured sub-
strates. (SI Results has a description of all mutants.)
N-sulfatase. There are no predicted sulfamidases in PULHep; how-
ever, GlcNS does not accumulate during growth on Hep, indicating
that Bt uses this sugar (Fig. S4F). We deleted the remaining
uncharacterized ORF in PULHep, bt4655. This mutant displayed a
growth defect on sulfated GAGs, and GlcNS accumulated in the
media during growth on Hep (Figs. S1F and S4F). These data in-
dicate that BT4655 cleaves the sulfamate linkage and is a pre-
viously uncharacterized class of sulfatase. Unfortunately, the
proposed role of BT4655 as a sulfamidase could not be confirmed
biochemically, because a soluble recombinant form of the protein
could not be generated.
The data show that the three sulfatases are key for both Hep and
HS breakdown. BT15962S-sulf is the first to act, removing 2-O sul-
fation from the limit PL-derived disaccharide and allowing
BT4658GH88 to hydrolyze its target linkage, because this enzyme
does not use 2-O–sulfated substrates. The sulfated glucosamine
monosaccharides are then substrates for BT46566S-sulf and the
likely sulfamidase BT4655 (Table S6).
Cytoplasmic Sugar Kinase. BT4654ROK is a cytoplasmic member of
the ROK protein family that possesses the conserved DxGxT motif
and thus, likely an ATP-dependent kinase (26). This activity was
confirmed by the capacity of the enzyme to phosphorylate gluco-
and manno-configured substrates but not galacto-configured sugars
(Table S6). The kcat/Km of the enzyme decreased from GlcN >
GlcNAc >> Glc/Man >> GlcNS, which was driven by increases in
Km (Table S6). These data show that O4 is critical for catalysis,
whereas strong selection in affinity is made at C2 for an equatorial
amine, indicating that BT4654ROK uses both an equatorial N2 and
an O4 as specificity determinants. Because the Δbt4654ROK mutant
displayed no growth defect on Hep or HS (Fig. S1F), Bt seems to
display redundancy in GlcN and GlcNAc phosphorylation.
Discussion
Bt PULHep orchestrates the hierarchical degradation of Hep and
HS. Both of these GAGs could be derived from dietary meat or
host glycans. In vivo expression of PULHep in mice colonized with
Bt has only been observed in bacteria occupying the mucosal layer,
suggesting that the source of Hep/HS available to Bt is from the
turnover of epithelial cells rather than the diet (27). HS could also
be supplied in the human diet as a component of meat; however,
colonic metagenomic data obtained in a study, which swapped
subjects from vegetarian diets to meat-rich diets, did not reveal any
PL families associated with the degradation of Hep/HS (28). These
data support the hypothesis that the source of Hep/HS in the hu-
man gut accessible to the microbiota is from the turnover of epi-
thelial cells. Goodman et al. (29) identified through transposon
mutagenesis genes in Bt important for colonization of the mouse
gut. Strains with insertions in the bt4659susD-like were significantly
decreased in the output from the monocolonized mouse gut
compared with input. Interestingly, in mice cocolonized with six
other Bacteroidetes strains in addition to the Btmutant population,
bt4658GH88 and bt4661SGBP insertion mutants were much lower in
abundance than in monocolonized mice, indicating that the ability
to degrade HS is under increased selection pressure for Bt in the
presence of other Bacteroidetes (Fig. S2).
Within the Hep-based GAGs, there is substantial structural di-
versity, especially in terms of the level of sulfation, and it is this
heterogeneity that provides an explanation for the distinct but
complementary activities of the enzymes encoded by the PULHep.
A key feature of the PULHep degradative apparatus is the surface
lyase, BT4662PL12, which although dispensable for growth on Hep,
plays a significant role in optimal HS utilization. This difference
likely reflects the high DP of HS relative to Hep, and thus, the
GAG needs to be subjected to a degree of extracellular de-
polymerization to generate molecules that can be imported into the
periplasm (5).
In the periplasm, the substrate specificity of endoprocessive ly-
ases is optimized to target highly sulfated (BT4675PL13) or low/
unsulfated regions (BT4657PL12), producing small oligosaccharides that
only the exoprocessive lyase (BT4652PL15) is able to degrade. This role
for BT4652PL15 is critical, because loss of the enzyme means
that elements of both Hep and HS remain inaccessible to Bt. The
presence of a PL15 lyase is a conserved feature of Hep/HS utili-
zation in other Bacteroidetes, supporting its key role in breakdown
of these GAGs (Fig. S2). The synergistic specificities displayed by
the PULHep lyases enable the bacterium to cleave the backbone of
GAGs that display substantial structural variation, particularly in
their sulfation patterns, leading to the generation of disaccharides.
The disaccharides are broken down by the complementary activ-
ities of the sulfatases and the GH88 enzyme-generating sugars that
can then be metabolized by the bacterium.
Bt places a high priority on Hep and HS utilization shown by the
lack of repression of PULHep by other polysaccharides and glucose
(30). HS is an abundant source of GlcNAc, which is required for
the synthesis of peptidoglycan. Although Bt seems to contain all of
the biosynthetic genes needed to make GlcNAc, it may still pri-
oritize GlcNAc derived from glycans to synthesize its cell wall. As
stated above, we propose that Bt uses HS/Hep from the host
mucosa rather than the diet. Because the epithelium is likely to
contain much higher amounts of HS compared with Hep, we be-
lieve that the biologically relevant glycan targeted by PULHep is
HS. Analysis of the genomes of other members of the CM revealed
PULs similar to Bt PULHep (Fig. S2). Bacteroides xylanisolvens and
Bacteroides ovatus both contain a predicted surface PL12 lyase
similar to BT4662PL12, suggesting that these organisms also target
HS. In contrast, the GAG-degrading apparatus of Bacteroides
intestinalis lacks an obvious surface Hep/HS lyase (Fig. S2). Thus,
the bacterium may target oligosaccharides or low molecular weight
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Fig. 4. Sulfatase structures. Upper shows cartoon representations of
(A) BT15962S-sulf and (B) BT46566S-sulf. 2Fo-Fc maps contoured at 1.0 sigma for
Δ4,5UA2Sβ1–4GlcNS6S in complex with BT15962S-sulf and GlcNS6S in complex
with BT46566S-sulf are shown in the respective enzymes active sites. Lower shows
stick representations of the active site interactions between (A) BT15962S-sulf and
Δ4,5UA2Sβ1–4GlcNS6S and (B) BT46566S-sulf and GlcNS6S. Amino acid side chains
are shown in green, the sugars are in yellow, and H bonds between the sugar
and protein are black dotted lines. Residues labeled in red are the key catalytic
amino acids.
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GAGs, such as Hep, which can be imported without the need for
enzymatic depolymerization.
The structural data of the sulfatases showed that the interactions
with the target sulfate are highly conserved in BT15962S-sulf,
BT46566S-sulf, and the human 6S GalNAc sulfatase (GALNSase)
(Fig. S3F). In BT46566S-sulf and GALNSase (the only other 6-O
carbohydrate sulfatase for which a structure is available; Protein
Data Bank ID code 4FDI), however, there is very little conservation
in the residues that interact with the carbohydrate component of the
substrate (Fig. S3G), showing that this area is highly variable and
could be the basis for bespoke highly specific glycosulfatase inhibi-
tors. Such inhibitors may have therapeutic relevance, because a re-
cent study showed that, in a colitis-sensitive mouse model, sulfatases
expressed by Bt are essential factors in inducing the disease (31).
Conclusions
This report describes the characterization of a PUL that orches-
trates the degradation of Hep/HS, high-priority heterogeneous
glycans. Unlike other microbial systems that remove side chains
before backbone degradation, the glycan backbone of Hep/HS is
depolymerized before removal of the sulfate groups. To achieve
this depolymerization, Bt expresses lyases with complementary
activities that, in combination, can fully deconstruct the Hep-based
GAGs. The PLs, sulfatases, and GH encoded by PULHep provide
an example of how an enzyme consortium can degrade substrates
that display highly variable sulfation patterns. Understanding the
mechanisms by which gut bacteria depolymerize GAGs may pro-
vide crucial insights into how the human gut microbiota is adapted
to use nonmucin host glycans and the role that this process plays in
colonization and survival in the gut. The model developed here can
be harnessed to interrogate metagenomic data to explore the
mechanisms by which different members of the microbiota me-
tabolize these complex GAGs.
Materials and Methods
Bacteroides Culture and Genetic Manipulation. Bt VPI-5482 was cultured an-
aerobically, and genomic null mutations were generated as described pre-
viously (16, 32).
Enzyme Assays. PL activity was monitored at A235. BT4658
GH88 glucuronyl hy-
drolase activity was determined by monitoring loss of signal at A235. Sulfatase
and kinase activities were determined through either linked assays or HPLC.
Products were analyzed by TLC and/or HPLC.
Crystallization of BT1596, BT4656, and BT4661. Crystallization and structure
determination were as described in SI Materials and Methods.
Full details of all experimental procedures used are described in SI Materials
and Methods.
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SI Materials and Methods
Sources of Carbohydrates. Carbohydrates were from Dextra Labo-
ratories, except for HS, which was either from Iduron or a gift from
J. Turnball (University of Liverpool, Liverpool, United Kingdom).
Bacteroides Culture and Genetic Manipulation. Bt VPI-5482 was
cultured anaerobically in a Whitley A35 Workstation (DonWhitley)
at 37 °C in either tryptone yeast extract glucose medium or min-
imal medium (MM) as described previously (5, 7). Bt strains
containing specific gene deletions or inactivated versions of en-
zymes were made by counterselectable allelic exchange as described
previously (32). The ΔBT4654ROK, ΔBT4655NS-Sulf, ΔBT4675PL13,
and ΔBT4662PL12 strains are all deletion mutants, whereas for the
ΔBT4652PL15 and Δ4657PL12 strains, only the key active site residues
were mutated in the respective enzymes. Growth of the WT and
mutants was measured on glycans by mixing the autoclave-sterilized
polysaccharides (1% final) with MM and monitoring growth con-
tinuously in 96-well plates using a Biotek Epoch plate reader.
Growth curves presented are averages of three biological replicates.
Microscopy. Glucose-grown cells were harvested at midexponential
phase and fixed for 90 min in formalin. Primary Ab was incubated
1/1,000 for 2 h at room temperature (RT), and secondary Ab (Santa
Cruz goat anti-rabbit FITC) at 1/500 was incubated at RT for 1 h.
Cells were mounted on ∼1.2% agar pads immobilized within a
Gene Frame (ABgene) using a 0.13- to 0.17-mm glass coverslip
(VWR). Microscopy was performed on an inverted epifluorescence
microscope (Zeiss Axiovert 200M) fitted with a Plan-Neofluar
objective (Zeiss 100×/1.30 Oil Ph3), a 300-W xenon arc lamp
transmitted through a liquid light guide (Sutter Instruments), and a
Sony CoolSnap HQ cooled CCD camera (Roper Scientific). All
filters were Modified Magnetron ET Sets from Chroma, and
details are available on request. Digital images were acquired
and analyzed with METAMORPH software (version V.6.2r6).
Proteinase K Treatment of Whole Cells.Cultures of Bt (100 mL) were
grown in MM with Hep as the sole carbon source to mid-
exponential phase (OD600 ∼ 0.6–0.8; monitored using a Biochrom
WPA cell density meter). Cells were harvested by centrifugation
and washed in 10 mL PBS before being resuspended in 5 mL
buffer. The cells were split into four 1-mL aliquots. To three of the
aliquots, 2 mg/mL Proteinase K was added and incubated at 37 °C
for 1–16 h, and the fourth sample was left as an untreated control
also for 16 h. After incubation with the protease, the samples were
centrifuged at 5,000 × g for 10 min, and the supernatant discarded.
The cell pellets were resuspended in 1 mL PBS, and the proteins
were precipitated by the addition of 200 μL trichloroacetic acid and
incubation on ice for 30 min. The precipitated proteins were pel-
leted by centrifugation and washed four times in 1 mL ice cold
acetone. The protein pellets were resuspended in 250 μL Laemmli
buffer and subjected to SDS/PAGE. Gels were transferred to
Whatman Protran BA 85 nitrocellulose membrane. Proteins of
interest were detected using antisera raised in rats against BT4661,
BT4662, or BT4657. The secondary antibody used was a chicken
anti-rat conjugated to HRP. Detection was by chemiluminescence
using Biorad Clarity Western ECL Substrate.
Coimmunoprecipitation. Immunoprecipitation was carried out using
a Pierce coimmunoprecipitation (co-IP) kit according to the man-
ufacturer’s instructions. Briefly, cells from 30 mL WT Bt grown on
MM Hep to midexponential phase were lysed using BugBuster
(Novagen), and solubilized extract was precleared with control
resin. The total lysed cell material was passed down an anti-
BT4661 antibody column (100 μL agarose resin prepared with
500 μg antibody and cross-linked as per the manufacturer’s in-
structions). The column was incubated with gentle rocking at 4 °C
for 16 h to pull out BT4661 and any interacting partners from the
lysate. The column was then washed extensively with Elution
buffer (pH 2.8; containing primary amines) at 4 °C, and material
remaining bound to the immobilized antibody was eluted with a
low pH buffer. Eluted fractions were neutralized with 1 M Tris,
pH 9.5, and anti-BT4661 (raised in rabbit) or anti-BT4659 (raised
in rat) antibodies used to probe membranes. Detection was by
anti-rabbit or -rat HRP-conjugated secondary.
Whole-Cell Assays. Bt was grown in 5 mL MM with 1% (wt/vol)
appropriate GAG or glucose as the sole carbon source to mid-
exponential phase in glass test tubes. Cells were harvested by
centrifugation at 5,000 × g for 10 min at room temperature and
washed in 5 mL PBS (pH 7.1) before being resuspended in 1 mL
PBS. Washed cells were assayed against 10 mg mL−1 of the ap-
propriate GAG at 37 °C for up to 72 h. Assays were analyzed by
TLC, and 2 μL each sample was spotted onto silica plates and
resolved in butanol:formate:water (4:8:1) buffer. The plates were
dried, and the sugars were visualized using diphenylamine stain.
Recombinant Protein Production. Genes were amplified by PCR
using the appropriate primers and the amplified DNA cloned in
pET28a using NcoI/XhoI or NheI/XhoI restriction sites generating
constructs with either N- or C-terminal His6 tags. Recombinant
genes were expressed with Escherichia coli strains BL21 (DE3)
or TUNER (Novagen), containing the appropriate recombinant
plasmid, and cultured to midexponential phase in LB supplemented
with 50 μg/mL kanamycin at 37 °C and 180 rpm. Cells were then
cooled to 16 °C, and recombinant gene expression was induced by
the addition of 0.1 mM isopropyl β-D-1-thiogalactopyranoside; cells
were cultured for another 16 h at 16 °C and 180 rpm. The cells were
then centrifuged at 5,000 × g and resuspended in 10 mM Hepes,
pH 7.5, with 500 mM NaCl before being sonicated on ice.
Recombinant protein was then purified by immobilized metal ion
affinity chromatography using a cobalt-based matrix (Talon, Clon-
tech) and eluted with 100 mM imidazole. For the proteins to un-
dergo structural studies (BT1596, BT4661, and BT4656), another
step of size exclusion chromatography was used using a Superdex
16/60 S200 (GE Healthcare), with 10 mM Hepes, pH 7.5, and
500 mM NaCl as the eluent, and they were judged to be ≥95% pure
by SDS/PAGE. Protein concentrations were determined by measuring
absorbance at 280 nm using the molar extinction coefficient calculated
by ProtParam on the ExPasy server (web.expasy.org/protparam/).
ITC. The affinity of BT4661SGBP and BT4659SusD-like for oligo- and
polysaccharides was quantified by ITC using a Microcal VP-ITC.
The protein sample (50 μM), stirred at 300 rpm in a 1.4-mL re-
action cell, was injected with 26 × 10-μL aliquots of ligand. Titra-
tions were carried out in 20 mMNa-Hepes buffer, pH 7.5, at 25 °C.
Integrated binding heats minus dilution heat controls were fit to a
single set of sites binding model to derive Ka, ΔH, and n (number
of binding sites on each molecule of protein) using Microcal Origin
v7.0. The molar concentration of binding sites present in polysac-
charides for each protein was determined by altering the concen-
tration of ligand used for regression of the isotherm until the fit
yielded a value of one for n.
SAXS Experiments. Purified BT4661SGBP (as described above) was
concentrated to ∼6 mg/mL using centricon devices with a cutoff of
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10 kDa. For BT4661 in complex with Hep (BT4661L), 1 mg/mL
ligand was added to the protein before concentrating the solution.
A dilution series with buffer at 10 mM Hepes, pH 7.5, 250 mM
NaCl, and 5% glycerol was prepared with and without 1 mg/mL
ligand to obtain five samples covering a concentration range from
0.8 to 5.9 mg/mL for BT4661 in the presence and absence of li-
gand. The protein samples were filtered through a Millex-GV filter
with a 0.22-μm cutoff PVDF membrane before each measurement.
SAXS experiments were carried out at the X33 beamline of the
European Molecular Biology Laboratory (Deutsches Electronen
Synchrotron) using a Pilatus 500Kdetector.A 4.2mg/mL solution of
BSAwas measured as a reference and for calibration. The scattering
patterns were measured with an exposure time of 4 × 30 s at 288 K.
The wavelength was 1.5 Å. The sample to detector distance was set
at 2.4 m, leading to scattering vectors q (defined as q = 4π/λsinθ,
where 2θ is the scattering angle) ranging from 0.06 to 0.5 Å−1.
SAXS curves were measured on protein samples with varied con-
centrations to check for interparticle interactions. Background
scattering was measured after each protein sample using the buffer
solution and then subtracted from the protein scattering patterns
after proper normalization and correction from detector response.
Absolute calibration was made with a Lupolen sample. Experi-
ments were carried out at a temperature of 20 °C.
Enzyme Assays.All assays, unless stated, were carried out in 50 mM
MES, pH 6.0, or Bis-Tris propane, pH 6.5, with 150 mM NaCl and
5 mM CaCl2 at 37 °C. PL activity was monitored continuously at
A235 by the formation of the carbon double bond generated
through the enzymes beta elimination mechanism of action.
BT4658GH88 glucuronyl hydrolase activity was determined by
monitoring loss of signal at A235. The ability of BT1596 to remove
O2 sulfation from unsaturated Hep disaccharides was monitored
continuously by the loss of signal at A235 by linked assay using
BT4658GH88 (inactive on O2-sulfated unsaturated Hep disaccha-
rides) to indirectly observe the loss of O2 sulfation. The ability of
BT46566S-sulf to remove O6 sulfation from GlcNAc6S was moni-
tored by the production of GlcNAc detected by high-pressure
anion exchange chromatography (HPAEC) with pulsed ampero-
metric detection using a carbohydrate standard quad waveform for
electrochemical detection at a gold working electrode with an
Ag/AgCl pH reference electrode and a Carbopac PA-100 guard
and analytical column (Dionex; ThermoFisher). The ability of
recombinant BT4654ROK to phosphorylate various sugars was eval-
uated by performing sugar kinase assays as described previously (33).
Briefly, ADP generated by the transfer of phosphate to a sugar
acceptor is used by pyruvate kinase to generate ATP and pyruvate,
which is used by lactate dehydrogenase to oxidize NADH to
NAD+, and thus, loss of absorbance at 340 nm can be used to
indirectly monitor sugar phosphorylation. Reaction profiles of PL
digestion of GAGs were monitored by HPAEC using an
AD25 absorbance detector at A235 to detect the carbon double-
bond products, with H2O, pH 3.5, as the eluent and a second
eluent of H2O with 3 M NaCl used to generate a linear NaCl
gradient to 50% over 80 min. For substrate depletion experiments,
the equation (kcat/Km)·t = ln(S0/St) was used, and the data were
fitted by linear regression. To determine all other kinetic data,
the initial rate vs. a range of substrate concentrations were fit to
the Michaelis–Menten equation by nonlinear regression using
Graphpad Prism 6.0. All assays were run in triplicate unless stated.
Crystallization of BT1596, BT4661, and BT4656. After purification,
BT4661 was dialyzed against ultrapure H2O, whereas BT1596 and
BT4656 were carried forward in the same eluent as used for the
size exclusion chromatography. All proteins were then concen-
trated in centrifugal concentrators with a molecular mass cutoff of
30 kDa. Sparse matrix screens were set up in 96-well sitting drop
TTP Labtech plates (400-nL drops). Initial BT1596 ligand-bound
crystals were obtained at 5 mg/mL with 10 mM ligand in 20% PEG
3350 and KCl. For BT4656, apo- and ligand-bound initial hits were
obtained at 20 mg mL−1 in 2 M NH4SO4, 0.1 M Na citrate, pH 5.6,
and 0.2 M Rochelle salts with 20% PEG 3350 and NaNO3, re-
spectively. Apo BT4661 was crystallized at 10 mg mL−1 in 18–23%
PEG 3350, 350 mM NaSO4, and 0.1 M Bis·Tris Propane, pH 8.0.
Truncated BT4661 was crystallized at 10 mg mL−1 with 5 mM Hep
hexasaccharide in 25% PEG 1500 and 100 mMMMT (1:2:2 –DL-
malic acid:MES:Tris base), pH 6. Data were collected at Diamond
Light Source (Oxford) on beamlines I02 and I04-1 (0.92 Å) at
100 K. The data were integrated with XDS and scaled with Aimless.
Five percent of observations were randomly selected for the Rfree
set. The phase problem was solved by molecular replacement using
the program Phaser for BT1596 with the Protein Data Bank (PDB)
search model ID code 3B5Q and the automated molecular re-
placement server Balbes for BT4656. The crystal structure of
BT4661 was solved using single-wavelength anomalous dispersion
(SAD) based on the selenomethionine (SeMet) sites. Structure
determination used programs in CCP4i. The sites and phases were
determined using the SHELXC/D/E pipeline in CCP4i using in-
tensities (34). Because of the similarity in cell dimensions between
the SeMet and the native crystal, the phases from the SAD ex-
periment could be transferred and extended to the higher-
resolution native dataset. The phase quality allowed us to use au-
tomated model building with ARP/wARP. The models were
completed using iterative cycles of refinement with refmac5 and
model-building using COOT. The dataset obtained from truncated
BT4661 crystallized in presence of ligand was solved with Molrep
using the corresponding PDB model from the native apo form.
Solvent molecules were added using ARP/wARP solvent and
checked manually. The model underwent cycles of model building
in COOT and refinement in Refmac5. All other computing used
the CCP4 suite of programs. The model was validated using
MolProbity, and data statistics, refinement details, and PDB ID
codes are reported in Table S2. Structure representations were
made using Pymol (version 1.74; Schrödinger).
Site-DirectedMutagenesis. Site-directed mutagenesis was conducted
using the PCR-based QuikChange kit (Stratagene) according to the
manufacturer’s instructions using the appropriate plasmid as the
template and appropriate primer pairs. Mutants of BT4661SGBP
were run on native PAGE gels in the presence or absence of Hep
(0.1% final; added to the gel before polymerization) to assess their
ability to bind the GAG.
Comparative Genomics Analysis. PULs similar to Bt PULHep were
searched for in >300 Bacteroidetes genomes. The identification of
similar PULs was based on a combination of PUL modular align-
ments and BlastP searches. Gene composition and order in all of
the Bacteroidetes PULs were first computed using the PUL pre-
dictor described in PULDB (35). Then, the predicted PULs were
aligned to PULHep according to their modularity as proposed in the
RADS/RAMPAGE method for protein alignment at the domain
level (36). Modules taken into account include CAZy families,
sensor regulators, sulfatases, and susCD-like genes. Finally, PUL
boundaries and limit cases were refined by BLASTP-based analysis
at the protein level.
SI Results
SAXS Data Analysis.The values of radii of gyration (Rg) were derived
from the Guinier approximation (37): I(q) = I(0)exp(−q2Rg2/3),
where I(q) is the scattered intensity, and I(0) is the forward scat-
tered intensity. The radius of gyration and I(0) are inferred from
the slope and the intercept, respectively, of the linear fit of Ln[I(q)]
vs. q2 in the q range q·Rg < 1.3. The distance distribution function
P(r) was calculated on the merged curve by the Fourier inversion
of the scattering intensity I(q) using GNOM (38). All scattering
curves were indicative of monomeric states of the molecules in
solution. The concentration dependence of the Rg value in the low
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q region (Table S3), however, was indicative of slight repulsive
interactions of the molecules in solution, but otherwise, the curves
registered at different concentrations were perfectly superimpos-
able. The lowest concentration curves were considered too noisy
and were not further taken into account. The estimated Rg value
from the Guinier approximation was, therefore, extrapolated at
zero concentration for both samples based on the linear correlation
of the four other concentrations. A merged curve using the low
concentration curve (1.7 mg/mL) in the low q region (<0.085 Å−1)
and the high concentration curve (5.9 mg/mL) was produced for
each of the proteins BT4661 with and without ligand and used in
subsequent steps.
The low-resolution shape of BT4661 and BT4661L in solution was
determined ab initio from the merged scattering curve using the
program GASBOR (39). This program restores low-resolution
shapes of proteins and calculates a volume filled with densely
packed spheres (dummy residues of 3.8-Å diameter), fitting the
experimental scattering curve by a simulated annealing minimization
procedure with a nearest neighbor distribution constraint and
leading to χ2 values of 0.99 and 1.00 for BT4661 and BT4661L,
respectively. In comparison, CRYSOL (40) was used to calculate the
fit of the crystal structure (PDB ID code 4AK1) to the experimental
scattering curve giving χ2 values of 2.07 and 4.72, respectively.
Several independent fits were run with no symmetry restriction,
and the stability and coherence of the solution were checked by
calculating normalized spatial discrepancy values of 1.62 (BT4661)
and 1.54 (BT4661L) for five independent calculations using
DAMAVER (41). The obtained envelopes were compared with
the crystal structure by superimposing the objects using PyMOL
(version 1.74; Schrödinger).
BT4657PL12 + 1 (Active Site) Specificity.When a mixture of two heavily
sulfated tetrasaccharides (4 and 5 in Fig. S4B) was treated with
BT4657PL12, only glycan 4 was digested, producing Δ4,5UA-
GlcNS6S and Δ4,5UA2S-GlcNS6S (Fig. S4C). This finding suggests
that 2-O sulfation is inhibitory to BT4657PL12 but leaves ambiguity
if it is at the +1 or −2 subsite [the scissile bound is between the
sugars at −1 and +1, with the nonreducing and reducing ends of the
substrate extending into the negative and positive subsites, re-
spectively (42)]. Treatment of the tetrasaccharide mix with BT1596,
a 2-O sulfatase that specifically removes 2-O sulfate groups from
the nonreducing end of Δ4,5UA, produced a tetrasaccharide
(glycan 6 in Fig. S4B) that was still not cleavable by BT4657 (Fig.
S4C). These data show that BT4657PL12 cannot tolerate 2-O sul-
fation of the UA at its +1 subsite and provide a biochemical basis
for its preference for HS and ΔSHep, which contain much lower
amounts of 2-O sulfation than Hep (Fig. 1).
Sulfatases Biochemical and Structural Characterization. BT15962S-sulf
and BT46566S-sulf both have a pocket topology with putative metal
binding sites located at the base of the pocket. In BT15962S-sulf, this
site comprises D40, H41, D299, and H300, whereas in BT46566S-sulf,
the side chains of D37, D38, D349, and Q350 fulfill this role. In
both proteins, the formylglycine residues and the catalytically labile
sulfate complete an octa-coordinated geometry of the bound metal.
A calcium ion could only be modeled into the site of BT46566S-sulf.
The importance of the metal binding site is shown by the obser-
vation that the mutations D37A, D38A, and D349A in BT4656 and
H300A in BT15962S-sulf completely inactivated the respective en-
zymes (Table S6). Neither enzyme could be inactivated by EDTA,
suggesting that the metal is either bound extremely tightly or in-
accessible to EDTA.
In BT15962S-sulf, the O2 sulfate group of the Δ4,5-unsaturated
UA makes potential ionic interactions with the Nζ of K133 and
K312 and hydrogen bonds to Nδ of N101 and Ne2 of H196, and it
may make polar contact with the backbone amine of the catalytic
residue S72. The mutations K133A and N106A caused substantial
reductions in catalytic activity, supporting the important role of the
lysine and asparagine in sulfate binding (Table S6). E394 interacts
with O3 of the unsaturated IdoA, and the E394A variant displayed
a 1,000-fold decrease in kcat/Km. Y395 interacts with the glycosidic
oxygen through its side chain. The Y395A mutation did not affect
kcat/Km but greatly increased Km and kcat. This result suggests that
the residue contributes to binding but does not contribute to tran-
sition state stabilization, whereas the commensurate increase in kcat
likely reflects increased rate of product departure (Table S6). The
reducing end GlcNS6S makes few interactions with BT15962S-sulf,
and R245 makes a hydrogen bond to O3 and a possible ionic in-
teraction with the N2 sulfate, both via Nδ2. There is also a potential
interaction between the O6 sulfate and Nζ of K133. Mutation of
R245 to Ala had the same effect as the Y395A mutation discussed
above, showing an important role in substrate binding. The Y395F
mutant was completely inactive, suggesting that the more hydro-
phobic nature of the side chain prevents substrate binding.
In BT46566S-sulf, the N98A and K362A mutations both inactivate
the enzyme (Table S6). N98 sits at the bottom of the active site and
interacts with the O6 sulfate via Nδ2. K362 potentially hydrogen
bonds to the thioester linkage of the O6 sulfate but also interacts
with D38 of the calcium binding site. Mutation of K362 could
potentially disrupt the metal binding site and thus, the loss of ac-
tivity of the K362A mutant. K125 seems to play an important role
in O6 sulfate binding, because K125A substitution resulted in a
1,000-fold reduction in activity. Q147 binds to the endocyclic ring
oxygen and the O6 sulfate via Ne2, and the Q147A variant causes
around a 30-fold reduction in activity (Table S6). The importance
of the interactions between E446 and O1 and N2 of the substrate is
illustrated by the 1,000-fold decrease in activity mediated by the
E446A mutation. The H447A substitution decreased activity 500-
fold, suggesting that H447 is the only residue making productive
interactions via O3.
Both BT1596 and BT4656 have predicted signal peptides (www.
cbs.dtu.dk/services/LipoP/), suggesting a periplasmic location for
these enzymes, consistent with the biochemical data. The likely
sulfamidase BT4655 is a predicted TAT protein (www.cbs.dtu.
dk/services/TatP/) and therefore, also likely periplasmic. Note that
the N-terminal methionine in each of these proteins is incorrect
in the database sequence and should be 23 residues downstream
in BT4656 (correct N term starts MKSN), 7 residues upstream in
BT1596 (correct N term starts MKTI), and 37 residues upstream
in BT4655 (correct N term starts MDRR).
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Fig. S1. Growth of WT and mutant strains of Bt on Hep, HS, and ΔSHep. (A) Mutant strains with deletions in PULHep glycan-binding proteins BT4661 and BT4659.
Left, Inset shows growth on heparin oligosaccharides. (B) BT4662 PL12 single- and BT4662 PL12/BT4652 PL15 double-mutant strains. (C) BT4652 PL15 mutant strain.
(D) BT4657 PL12 single- and BT4657/BT4652 PL15 double-mutant strains. (E) BT4675 PL13 single- and BT4675 PL13/BT4652 PL 15 double-mutant strains. (F) BT4655
NS sulfatase and BT4654 GlcNAc kinase mutant strains. All growths were performed in MM supplemented with 10 mg/mL appropriate polysaccharide. OD600
measurements were taken every 20 min after bacterial inoculation using a plate reader.
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Fig. S3. Cellular localization of proteins encoded by PULHep, SAXS curves, and key binding residues of BT4661
SGBP and comparison of the active sites of the
sulfatases with structural homologs. (A) Immunofluorescence labeling of Glc-grown WT or ΔBT4661 cells with (Left) anti-4661 antibody or (Right) phase contrast.
(B) Western blots showing Hep-grown whole cells treated with proteinase K and probed with polyclonal antibodies raised against recombinant forms of
BT4661SGBP, BT4662PL12, and BT4657PL12. Proteinase K cannot cross the outer membrane and therefore, can only act on surface-located proteins, revealing that
BT4661SGBP and BT4662PL12 are surface-located, whereas BT4657PL12 is most likely periplasmic. (C) Co-IP of BT4661SGBP and BT4659SusD-like from lysate of Hep-grown
cells using anti-BT4461 polyclonal antibody immobilized to agarose beads. IP, immunoprecipitation. (D) Experimental SAXS curves and the fitted scattering profiles
calculated by GASBOR. Experimental merged data are shown as gray triangles (liganded BT4661SGBP) or blue circles (apo BT4661SGBP). The scattering curves fitted
with GASBOR are shown as solid lines. lnl, logarithmic representation of intensity; q, scattering angle in angstroms−1. (E) Affinity gel electrophoresis of BT4661SGBP
alanine mutants of residues that interact with the fully sulfated Hep-derived hexasaccharide ligand. Upper shows native gel with no added ligand, and Lower
shows native gel with added Hep (0.1% final). Loss of retardation of K505A, R581A, and R582A on the Hep gel reveals that these residues are critical in ligand
recognition. (F) Overlay of BT46566S-sulf (green), human galactosamine-6-sulfatase (PDB ID code 4FDI; magenta), and BT15962S-sulf (cyan), showing the conservation
in the catalytic center. The sulfate groups shown are bound to BT46566S-sulf and BT15962S-sulf, whereas the calcium ions are bound to BT46566S-sulf and 4FDI. Note
that residue 89 in 4FDI is formyl glycine (FG). (G) Overlay of BT46566S-sulf with GlcNS6S bound (green), 4FDI (magenta), and BT15962S-sulf with 4,5UA2S-GlcNS6S
bound (cyan), showing variability in the glycone binding region. For clarity, only the sugar interacting with the protein has been shown.
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Fig. S4. Activity of whole cells and recombinant PULHep enzymes against Hep and Hep oligosaccharides and evidence that BT4655 is a sulfaminidase. (A) Activity of
whole cells and recombinant lysases (0.1 μM) against Hep (10 mg/mL). Top shows cells grown on Glc or Hep as the sole carbon source to midexponential phase,
washed, and assayed against Hep to determine surface enzyme activity. Middle and Bottom are products released by recombinant forms of the different PUL-
encoded lyases against Hep. Di and Tet are Hep disaccharide and tetrasaccharide standards, respectively (structures 2 and 5, respectively, in B). (B) Identity of the
sugars labeled in C and D. (C) Chromatograms showing sulfate tolerances of BT4657PL12 against 4, a sulfated tetrasaccharide lacking a single O2 sulfation, and 5, a
fully sulfated tetrasaccharide, pre- and postaddition of BT15962S-sulf. (D) Chromatograms showing exoprocessivity of BT4652PL15 against Hep oligosaccharides (all at
50 μM substrate). (E) TLC analysis of BT4662PL12 and BT4657PL12 product profiles against ΔSHep (10 mg/mL). (F) Supernatants of stationary-phase WT and
ΔBT4655NS-Sulf cells grown on Hep. GlcNS lane is a standard.
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Table S1. ITC data for BT4659SusD-like and BT4661SGBP
Ligand Protein Ka × 10
4, M−1 ΔH, kcal·mol−1 TΔS, kcal·mol−1 n
Polysaccharides
HS BT4659SusD-like 1.4 (±0.6) −14.0 (±0.3) −8.3 1.0 (±0.01)
BT4661SGBP 27.0 (±4.0) −9.2 (±0.1) −1.8 1.0 (±0.04)
Hep BT4659SusD-like 1.5 (±0.2) −21 (±5.0) −15.3 0.8 (±0.1)
BT4661SGBP 40.0 (±9.0) −9.7 (±0.3) −2.1 1.0 (±0.02)
ΔSHep BT4659SusD-like 2.1 (±0.4) −9.6 (±0.2) −3.7 0.9 (±0.2)
BT4661SGBP 11.0 (±8.1) −4.6 (±1.5) 2.3 1.0 (±0.01)
Hep oligosaccharides
Dp2 BT4659SusD-like NB
BT4661SGBP NB
Dp4 BT4659SusD-like NB
BT4661SGBP* 8.5 (±0.4) −6.5 (±0.1) 0.2 0.8 (±0.01)
Dp6 BT4659 SusD-like NB
BT4661SGBP* 31.0 (±2.0) −8.3 (±0.1) −0.8 0.8 (±0.01)
Dp8 BT4659SusD-like NB
BT4661SGBP 37.0 (±1.0) −8.7 (±0.2) −1.1 0.7 (±0.01)
Dp10 BT4659SusD-like NB
BT4661SGBP* 55.0 (±3.0) −13.0 (±0.1) −5.2 0.5 (±0.01)
Data are averages and SDs of at least two replicates, except where indicates. NB, no binding at the maximum
concentration tested (1 mM for oligosaccharides).
*Data are from a single titration with errors of fit.
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Table S3. Experimental radius of gyration (Rg), forward scattered intensity [I(0)],
and maximal distances (Dmax) values extracted from the SAXS curves of
BT4661 and BT4661 + ligand (BT4661L)
Protein
Rg or extrapolated
Rg, Å Mw from I0
I(0) or Rg
from P(r)
Dmax from
P(r), Å
[BT4661] (mg/mL)
0.75 4.33 92
1.48 4.33 90
2.87 4.15 90
4.54 4.05 86
5.77 4.00 79
Bt4661 4.43 78.8 4.58 150
[BT4661L] (mg/mL)
0.78 4.40 96
1.67 4.30 90
3.09 4.12 90
4.52 4.08 93
5.97 3.98 90
Bt4661L 4.43 78.8 4.43 150
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Table S4. Catalytic activities of the PULHep-encoded PLs
Substrate and enzyme Km, mg·mL or μM kcat, min−1 kcat/Km, min−1 mg−1·mL or min−1 M−1
Hep*
BT4662PL12 >8 — 325 (±28)
BT4657PL12 <0.5 2,389 (±463) —
BT4675PL13 <0.1 4,447 (±54) —
BT4652PL15 0.68 (±0.20) 500 (±49) 787 (±234)
HS*
BT4662PL12 >2 — 819 (±85)
BT4657PL12 0.036 (±0.011) 1,193 (±167) 33,139 (±9,842)
BT4675PL13 <0.1 3,587 (±68) —
BT4652PL15 >2.0 — 740 (±48)
ΔSHep*
BT4662PL12 >8 — 120 (±13)
BT4657PL12 0.079 (±0.002) 1,856 (±167) 23,512 (±2,514)
BT4675PL13 NA NA NA
BT4652PL15 >8 — 0.92 (±0.09)
Hep DP = 4
BT4662PL12 NA NA NA
BT4657PL12 NT NT NT
BT4675PL13 — 108 (±15) —
BT4652PL15† 4.4 (±0.5) 1,023 (±158) 4.9 × 108 (±1.3 × 107)
Hep DP = 6
BT4662PL12 NA NA NA
BT4657PL12 NT NT NT
BT4675PL13 — 1,904 (±361) —
BT4652PL15 16.5 (±3.1) 2,316 (±186) 1.5 × 108 (±2.2 × 107)
Hep DP = 8
BT4662PL12 NA NA NA
BT4657PL12 NT NT NT
BT4675PL13 — 890 (±214) —
BT4652PL15† 18.6 (±1.2) 3,349 (±56) 1.9 × 108 (±1.1 × 107)
Hep DP = 10
BT4662PL12 — — 1.5 × 106 (±3.1 × 105)
BT4657PL12 NT NT NT
BT4675PL13 NT NT NT
BT4652PL15† ≥70 — 3.5 × 107 (±1.2 × 106)
Buffer composition was 50 mMMES, pH 6.0, with 150 mM NaCl and 2 mM CaCl2. NA, no activity detected; NT,
substrate was not tested.
*Polysaccharide data are in milligrams per milliliter.
†Experiments were technical duplicates.
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Table S5. Lyase end point assays
Enzyme(s) Hep, mM/mg (%) HS, mM/mg (%) ΔSHep, mM/mg (%)
BT4662PL12 0.1 ± 0.004 (5) 1.0 ± 0.022 (38) 3.1 ± 0.08 (82)
BT4657PL12 0.5 ± 0.01 (27) 1.4 ± 0.02 (54) 3.7 ± 0.06 (100)*
BT4675PL13 1.7 ± 0.11 (94) 1.5 ± 0.04 (56) N/A
BT4652PL15 1.7 ± 0.06 (95) 1.5 ± 0.002 (58) Incomplete
BT4652PL15/BT4675PL13 1.8 ± 0.01 (99) 1.9 ± 0.02 (71) —
BT4652PL15/BT4657PL12 1.7 ± 0.01 (99) 2.4 ± 0.02 (91) —
BT4675PL13/BT4657PL12 1.6 ± 0.07 (93) 2.1 ± 0.11 (80) —
BT4652PL15/BT4662PL12 1.7 ± 0.02 (98) 2.5 ± 0.22 (93) —
BT4662PL12/BT4675PL13 1.4 ± 0.04 (77) 2.2 ± 0.04 (84) —
BT4662PL12/BT4657PL12 0.5 ± 0.01 (29) 1.5 ± 0.01 (59) —
BT4652PL15/BT4675PL13/BT4657PL12 1.7 ± 0.01 (95) 2.4 ± 0.02 (92) —
BT4652PL15/BT4675PL12/BT4662PL12 1.7 ± 0.05 (95) 2.2 ± 0.04 (86) —
BT4652PL15/BT4657PL12/BT4662PL12 1.8 ± 0.01 (100)* 2.6 ± 0.03 (100)* —
BT4675PL13/BT4657PL12/BT4662PL12 1.4 ± 0.02 (82) 2.3 ± 0.02 (89) —
BT4652PL15/BT4657PL12/BT4675PL13/BT4662PL12 1.7 ± 0.01 (95) 2.5 ± 0.05 (97) —
N/A, not active.
*100% is the maximum digestion observed with any lyase combination for that particular GAG and was then used to normalize other
values against the same GAG. Buffer composition was 50 mM MES, pH 6.0, with 150 mM NaCl and 2 mM CaCl2.
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Table S6. Catalytic activities of the PULHep-encoded O-sulfatases, the GH88, and ROK kinase
Substrate Enzyme Km (mM) kcat (min
−1) kcat/Km (min
−1·M−1)
GH88
UA-GlcNS* BT4658 0.1 (±0.002) 2,211 (±600) 1.8 × 107 (±4.6 × 106)
UA-GlcNAc6S* BT4658 >0.1 — 1.7 × 107 (±5.1 × 106)
UA-GlcNAc* BT4658 >0.15 — 5.0 × 106 (±2.3 × 105)
2O-Sulfatase
UA2S-GlcNAc6S BT1596 >100 — 5.5 × 105 (±1.3 × 105)
UA2S-GlcNAc BT1596 >150 — 3.6 × 105 (±9.5 × 104)
UA2S-GlcNS6S BT1596† 0.4 (±0.05) 198 (±34) 5.2 × 106 (±1.2 × 106)
UA2S-GlcNS6S BT1596H33A 1.0 × 103 (±5.4 × 101)
UA2S-GlcNS6S BT1596N101A 6.6 × 103 (±4.9 × 102)
UA2S-GlcNS6S BT1596K133A 1.6 × 104 (±2.6 × 103)
UA2S-GlcNS6S BT1596R245A 2.2 × 106 (±1.4 x105)
UA2S-GlcNS6S BT1596R246A 2.1 × 103 (±6.8 × 101)
UA2S-GlcNS6S BT1596E394A 4.3 × 103 (±5.7 × 102)
UA2S-GlcNS6S BT1596Y395A 1.2 × 106 (±1.0 × 105)
6O-Sulfatase
GlcNAc6S BT4656† — — 2.0 × 105 (±4.0 × 104)
GlcNAc6S BT4656K125A 1.6 × 102 (±1.3 × 101)
GlcNAc6S BT4656Q147A 6.9 × 103 (±4.6 × 102)
GlcNAc6S BT4656R200A 9.8 × 104 (±6.1 × 103)
GlcNAc6S BT4656R363A 2.0 × 102 (±9.9 × 101)
GlcNAc6S BT4656E446A 1.1 × 103 (±8.0 × 101)
GlcNAc6S BT4656H447A 2.6 × 102 (±2.3 × 101)
ROK
GlcN BT4654 0.2 (±0.02) 4,581 (±684) 3.1 × 107 (±3.9 × 106)
GlcNAc BT4654 4.1 (± 0.4) 3,449 (±895) 8.7 × 105 (±3.1 × 105)
GlcNS BT4654 — — 3.4 × 101 (±1.1)
Glucose BT4654 114 (±5) 1,296 (±238) 1.1 × 104 (±2.1 × 103)
Mannose BT4654 37 (±9) 867 (±115) 2.4 × 104 (±2.9 × 103)
ManN BT4654 19 (±4) 33 (±2) 6.2 × 102 (±4.1 × 101)
ATP‡ BT4654 0.9 (±0.3) 1,954 (±114) 2.4 × 106 (±5.7 × 105)
*The GH88 displayed no activity against the UA2S versions of these disaccharides.
†WT BT1596 and BT4656 sulfatases are actually S72C and S77C mutants, respectively, because E. coli can only
convert cysteine to the formylglycine required for activity. Note that the S72A, H196A, D299A, H300A, and
Y395F mutants of BT1596 and the S77A, D37A, D38A, N98A, H199A, D349A, D361A, and K362A mutants of
BT4656 displayed no detectable activity. In addition, the H135A and K312A mutants of BT1596 and the H127A,
W249A, R266A, and Q350A mutants of BT4656 were made, but recombinant forms failed to express.
‡Values were determined using GlcNAc as the saturating sugar at concentration of 50 mM. The buffer used was
100 mM Tris·HCl, pH 8.0.
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